Immuron Limited Quick Ratio (IMRN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immuron Limited  (NASDAQ: IMRN)

Immuron Limited's Quick Ratio

IMRN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 1.44 a new company low.

Within Major Pharmaceutical Preparations industry 340 other companies have achieved higher Quick Ratio than Immuron Limited in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 1506.

Explain Quick Ratio?
How much Cash & cash equivalents IMRN´s has?
What are IMRN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMRN Quick Ratio (Jun 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Jun 30 2024)
Q4
Y / Y Current Liabilities Change -28.28 % -28.28 % -26.04 % -27.15 % -46.3 %
Y / Y Cash & cash equivalent Change -76.1 % -76.1 % -42.95 % -75.72 % -25.07 %
Quick Ratio MRQ 1.44 1.44 1.01 1.44 4.32
IMRN's Total Ranking # 1506 # 0 # # #
Seq. Current Liabilities Change 0 % -52.12 % 37.27 % 9.11 % 0 %
Seq. Cash & cash equivalent Change 0 % -31.64 % -3.85 % -63.63 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 341
Healthcare Sector # 613
Overall Market # 1506


Quick Ratio Statistics
High Average Low
22.33 7.47 1.44
(Jun 30 2021)   (Jun 30 2025)




Financial Statements
Immuron Limited's Current Liabilities $ 1 Millions Visit IMRN's Balance sheet
Immuron Limited's Cash & cash equivalent $ 2 Millions Visit IMRN's Balance sheet
Source of IMRN's Sales Visit IMRN's Sales by Geography


Cumulative Immuron Limited's Quick Ratio

IMRN's Quick Ratio for the trailling 12 Months

IMRN Quick Ratio

 (Jun 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -27.15 % -32.56 % -26.57 % 5.78 % 20.84 %
Y / Y Cash & cash equivalent TTM Growth -71.02 % -56.08 % -44.79 % -52.47 % -41.02 %
Quick Ratio TTM 1.28 1.96 2.55 2.51 3.21
Total Ranking TTM # 3091 # 0 # # #
Seq. Current Liabilities TTM Growth -6.57 % -6.16 % -10.31 % -7.36 % -13.5 %
Seq. Cash & cash equivalent TTM Growth -38.98 % -28.05 % -8.84 % -27.59 % -7.53 %

Quick ratio ranking by company, industry and sector >> Back to IMRN Financial Strength Comparisons >> Go to Compare IMRN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in IMRN's Current Liabilities to $1.29 millions, cumulative Quick Ratio to 1.28 below the IMRN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Immuron Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 3091.

Explain Quick Ratio?
How much Cash & cash equivalents IMRN´s has?
What are IMRN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 899
Within the Market # 3091


trailing twelve months Quick Ratio Statistics
High Average Low
22.33 10.9 4.28
(Jun 30 2022)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Damora Therapeutics Inc   3.88 $ 10.211  Millions$ 2.629  Millions
Maravai Lifesciences Holdings Inc   3.87 $ 269.907  Millions$ 69.682  Millions
Tvardi Therapeutics Inc   3.84 $ 40.994  Millions$ 10.678  Millions
Ligand Pharmaceuticals Incorporated  3.79 $ 245.020  Millions$ 64.734  Millions
Cyclerion Therapeutics Inc   3.76 $ 3.006  Millions$ 0.800  Millions
Ataibeckley Inc   3.76 $ 95.943  Millions$ 25.547  Millions
Lipella Pharmaceuticals Inc   3.72 $ 2.782  Millions$ 0.747  Millions
Aclaris Therapeutics Inc   3.72 $ 99.806  Millions$ 26.839  Millions
Immuneering Corporation  3.70 $ 26.355  Millions$ 7.120  Millions
Entrada Therapeutics Inc   3.66 $ 72.482  Millions$ 19.803  Millions
Bullfrog Ai Holdings Inc   3.63 $ 2.474  Millions$ 0.681  Millions
Clearside Biomedical Inc   3.52 $ 9.376  Millions$ 2.666  Millions
Xoma Royalty Corporation  3.49 $ 75.060  Millions$ 21.495  Millions
Processa Pharmaceuticals Inc   3.39 $ 6.937  Millions$ 2.049  Millions
Macrogenics Inc   3.35 $ 130.686  Millions$ 39.000  Millions
Cadrenal Therapeutics Inc  3.32 $ 5.571  Millions$ 1.680  Millions
Revelation Biosciences Inc   3.30 $ 5.174  Millions$ 1.569  Millions
Verastem Inc   3.26 $ 164.322  Millions$ 50.361  Millions
Biohaven Ltd   3.26 $ 404.980  Millions$ 124.324  Millions
Lantern Pharma Inc   3.26 $ 15.902  Millions$ 4.884  Millions
Gyre Therapeutics Inc   3.21 $ 54.365  Millions$ 16.920  Millions
Biomea Fusion Inc   3.20 $ 56.224  Millions$ 17.568  Millions
Ptc Therapeutics inc   3.17 $ 1,989.150  Millions$ 627.809  Millions
Io Biotech Inc   3.17 $ 28.131  Millions$ 8.888  Millions
Cocrystal Pharma Inc   3.15 $ 4.766  Millions$ 1.514  Millions
Longeveron Inc   3.15 $ 10.334  Millions$ 3.284  Millions
Can fite Biopharma Ltd   3.03 $ 6.456  Millions$ 2.128  Millions
Ardelyx inc   2.92 $ 238.452  Millions$ 81.722  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Shuttle Pharmaceuticals Holdings Inc   2.85 $ 4.818  Millions$ 1.693  Millions

Date modified: 2026-07-07T11:25:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.